Onyx Healthcare (ROCO:6569) Research & Development: NT$112 Mil (TTM As of Dec. 2025)


ROCO:6569 Onyx Healthcare Inc ROCO:6569
75 GF Score
Price NT$106.50
GF Value NT$121.39
Valuation Modestly Undervalued
! 7 Warning Signs
View Full Analysis

What is Onyx Healthcare Research & Development?

Onyx Healthcare ROCO:6569 75 Research & Development is NT$112 Mil as of Dec. 2025. GuruFocus rates ROCO:6569 with a GF Score™ of 75/100 and a GF Value™ of NT$121.39 (Modestly Undervalued). The stock has 7 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Onyx Healthcare's Research & Development for the three months ended in Dec. 2025 was NT$23 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was NT$112 Mil.

Onyx Healthcare  (ROCO:6569) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Onyx Healthcare Research & Development Related Terms

Onyx Healthcare Research & Development Historical Data

* Premium members only.

The historical data trend for Onyx Healthcare's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Onyx Healthcare Research & Development Chart

Onyx Healthcare Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 79.35 86.67 79.36 118.32 112.49

Onyx Healthcare Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 32.08 30.08 27.51 31.70 23.21
ROCO:6569
75GF Score
Onyx Healthcare Inc ROCO:6569
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Onyx Healthcare Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$112 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of NT$112 Mil mean?
Onyx Healthcare (ROCO:6569) has a Research & Development of NT$112 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Onyx Healthcare and its competitors.
Is Onyx Healthcare's Research & Development too high?
Onyx Healthcare's current Research & Development is NT$112 Mil. Overall, Onyx Healthcare has a GF Score™ of 75/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Onyx Healthcare's Research & Development compare to VEEV and BTSG?
Onyx Healthcare's Research & Development of NT$112 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Healthcare Providers & Services company?
A good Research & Development depends on the Healthcare Providers & Services industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Onyx Healthcare and its competitors. Onyx Healthcare's current Research & Development is NT$112 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Onyx Healthcare stock overvalued right now?
Based on GuruFocus' analysis, Onyx Healthcare (ROCO:6569) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$121.39, compared to a current price of NT$106.50 — trading 12.3% below its estimated fair value. The current Research & Development is NT$112 Mil. Onyx Healthcare's overall GF Score™ is 75/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Onyx Healthcare (ROCO:6569), the current Research & Development is NT$112 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Onyx Healthcare (ROCO:6569) Overvalued in 2026?

Based on GuruFocus' analysis, Onyx Healthcare stock appears to be undervalued. The current stock price of NT$106.50 is trading 12.3% below its estimated GF Value™ of NT$121.39. GuruFocus considers Onyx Healthcare to be Modestly Undervalued.

Key valuation signals for ROCO:6569:

  • Research & Development: NT$112 Mil
  • GF Value™: NT$121.39 vs. price of NT$106.50 (12.3% below fair value)
  • GF Score™: 75/100 with 7 warning signs

No single metric tells the full story. See the ROCO:6569 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Onyx Healthcare Business Description

Address No. 135, Lane 235, Baoqiao Road, 4th Floor, Xindian District, New Taipei, TWN, 231028
Onyx Healthcare Inc is engaged in designing, manufacturing, and trading of medical computers and peripherals. The company provides medical products such as AI Ready Medical PC and Tablet, Medical PC & Monitor for Digital OR (ACCEL), Telemedicine, Medical Cart Computer(Venus), Medical Power Panel PC (Mini Venus), Power Bank (UPower), Battery Management System (ORION), Mobile Medical Tablet (MD), Professional Medical All in One PC (ZEUS), etc. It operates in Taiwan, the United States, Europe, and Other countries and generates maximum revenue from Taiwan.
75GF Score

Get the complete analysis for ROCO:6569

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$106.50
Price
NT$121.39
GF Value